Lilly's bet on pain stands out amid bare pharma pipeline; AnaptysBio's new allergy data has investors scratching their heads; Aetna to offer point of sale pharmacy rebates to 3M customers; Protagonist halts colitis study after missed endpoint
A decision to exclude four patients with mild baseline symptoms from an interim analysis muddied otherwise positive results for its anti-inflammation drug.
Clinical trials of drug treatments for Central Nervous System diseases follow oncology as the second largest area of pharmaceutical research in terms of R&D spending, but the success rate has been low and approvals rare.
Jefferies called the drug a potential blockbuster and noted that, with strong Phase 2 data in hand, Verona would have a "compelling out-licensing opportunity in 2-3 years' time."
Our mission is to provide busy execs like you with an overview of the BioPharma industry in 60 seconds. BioPharma Dive is a product of Industry Dive. View other Industry Dive publications.
This email is optimized for display on mobile phones. BioPharma Dive is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to [email protected]. You can unsubscribe or change which newsletters you receive anytime. See our full privacy policy.
